Latest Health News

Paragon Care Limited reported a robust 22% increase in revenue to $3.61 billion for FY25, driven by organic growth and key acquisitions including CH2 Holdings and Oborne Health Supplies. The company also refinanced its debt facilities and expanded into the dental market post-year-end.

EBOS Group Limited reported a steady FY25 with 12% revenue growth and EBITDA in line with guidance, driven by strong healthcare and animal care segments. The company signals confidence with maintained dividends and a positive FY26 outlook.

Yancoal Australia has appointed Sharif Burra as its permanent CEO, signaling leadership continuity amid a challenging coal market. Burra’s deep internal experience positions him to build on recent operational gains and shareholder value.

Locate Technologies Limited reported a significant reduction in losses for FY2025, driven by strong growth in its Locate2u segment and effective cost management.

Audeara Limited reported a 19% revenue increase to $3.79 million for FY25, driven by strong Australian wholesale growth and expanding international partnerships. Despite a net loss of $1.79 million, the company’s AUA Technology division and new licensing deals position it for future profitability.

Dubber Corporation Limited will record a significant non-cash impairment charge in FY25 following the loss of a major customer contract with Virgin Media O2, impacting its intangible assets from a prior acquisition.

Wagners Holding Company Limited reported a 120% increase in net profit after tax for FY25 despite a 10.4% revenue decline, driven by strong segment performance and cost management. The company also declared a higher fully franked final dividend of 3.2 cents per share.

Star Combo Pharma has reported a remarkable jump in profit for FY2025, driven by strong revenue growth and a settled insurance claim, while declaring its second dividend and planning production expansion.

WAM Active Limited has announced a fully franked ordinary dividend of AUD 0.03 per share for the six months ending June 2025, accompanied by a Dividend Reinvestment Plan with no discount.

Emyria has begun treating the first Medibank-funded PTSD patients at its Perth clinic, marking a pioneering step in private insurance coverage for psychedelic-assisted therapy in Australia. This milestone fuels rapid clinic expansion and supports the company’s national rollout strategy.

Neurizon Therapeutics reported a $16.6 million loss for FY2025 amid significant progress in its lead neurodegenerative therapy NUZ-001, including regulatory milestones and a global licensing deal. The company is poised to enter a pivotal ALS clinical trial pending FDA clearance.

SKS Technologies Group Limited has reported a remarkable 112% increase in net profit for the financial year ended June 2025, alongside a near doubling of revenue. The company also declared fully franked dividends, signaling confidence in its financial health.